We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 712

El TJUE se pronuncia de nuevo sobre la Directiva 89105CEE, relativa a la transparencia de las medidas que regulan la fijación de precios de los medicamentos para uso humano y su inclusión en el ámbito de los sistemas nacionales del seguro de enfermedad
  • Gómez-Acebo & Pombo Abogados
  • European Union
  • June 1 2015

La Directiva 89105CEE del Consejo, de 21 de diciembre de 1988, relativa a la transparencia de las medidas que regulan la fijación de precios de los

Actualidad Normativa N.º 8
  • Gómez-Acebo & Pombo Abogados
  • European Union, Spain
  • July 21 2014

En materia medioambiental consideramos de interés las siguientes normas: El Real Decreto 1632014, de 14 de marzo, por el que se crea el Registro de

Canada-Europe Free Trade Agreement: a new prescription for drug patents in Canada
  • DLA Piper LLP
  • Canada, European Union
  • October 31 2013

On October 17, Canadian Prime Minister Stephen Harper flew to Brussels to conclude a Comprehensive Economic and Trade Agreement ("CETA"), or free

Global corporate insurance & regulatory bulletin
  • Mayer Brown JSM
  • China, European Union, United Kingdom, USA
  • December 5 2013

The China Insurance Regulatory Commission (“CIRC”) announced new rules (Implementing Rules of Provisional Measures on Outbound Investments with

Horizonte 2015
  • Norton Rose Fulbright LLP
  • European Union, Germany
  • February 11 2015

Seit Mitte 2013 können wir durch unsere Präsenz auch im US-amerikanischen Markt ein globales Profil anbieten, das den vielfältigen Anforderungen

Commission targets Belgium on health insurance
  • McDermott Will & Emery
  • Belgium, European Union
  • May 9 2008

The European Commission has asked Belgium to amend its national rules to ensure that EU insurance directives are applied to private sickness funds when they offer complementary health insurance cover outside the scope of the mandatory social security requirements

Updates on international pricing issues for pharmaceutical and biologic products
  • Sidley Austin LLP
  • China, European Union, France, Germany, United Kingdom, USA
  • May 18 2012

Sidley Austin LLP’s Global Life Sciences Team is pleased to provide you with this Global Pricing Newsletter, the first in a periodic series updating clients and friends of the firm on pricing issues around the world that may have an impact on pharmaceutical and biologic manufacturers’ legal and business strategies

Indemnity arrangements for healthcare professionals: long overdue
  • Kennedys Law LLP
  • European Union, United Kingdom
  • July 26 2013

The Department of Health's consultation on the implementation of the Health Care and Associated Professions (Indemnity Arrangements) Order 2013 (the

Johnson & JohnsonNovartis another challenge to pay for delay: is this ever permissible?
  • Bryan Cave LLP
  • European Union, France, Germany, Italy, United Kingdom
  • January 14 2014

In the latest challenge to so-called “pay for delay” or “reverse payment” agreements, on 10 December 2013, the European Commission fined the

Food companies should revisit insurance program and other risk management in light of emerging massive European Union E.coli outbreak
  • Stoel Rives LLP
  • European Union
  • June 1 2011

The E. coli outbreak unraveling now in the European Union, centered primarily in Germany, is setting new records for both the number of affected persons and the number of persons diagnosed with Hemolytic Uremic Syndrome (HUS), a serious complication from E. coli infection (HUS can lead to kidney failure, brain damage and death